South and Central America Histopathology Services Market Growth Drivers and Forecast by 2028

The South and Central America histopathology services market is expected to reach US$ 1,284.36 million by 2028 from US$ 962.78 million in 2021; it is estimated to grow at a CAGR of 4.2% from 2021 to 2028.

The histopathology market for biologics is growing at an unprecedented rate owing to expansion of biologics pipeline, increase in manufacturing complexity, and shift in the focus of companies toward core activities. A boom has been witnessed in the manufacturing of biologics. There is pressing need of scaling up the production once novel technologies get approval from the domestics and international approving bodies. The biopharmaceuticals industry is becoming fiercely competitive with the introduction of more biological products and biosimilars in the market. Biologics manufacturers strive to keep manufacturing costs low, deliver high-quality drugs, improve process efficiency, and accelerate market entry. Inputs from expert histopathologists have been playing a significant role in the understanding of tumor biology as well as in the pathogenic mechanism of various microorganisms. These findings and inferences are utilized by dedicated organizations offering histopathological services. Clinical trials and drug discovery procedures of these drugs are based on intrinsic histopathological studies conducted using high-tech equipment, under expert supervision. The escalating incidence of chronic diseases such as cardiovascular disorders, neurological disorders, autoimmune disorders, and cancer is a leading causes of mortalities and disabilities worldwide. Researchers and therapists are exploring therapies for treating these diseases; they conduct detailed histopathological analysis to understand the pathophysiology of these diseases for designing therapies, which is contributing to the histopathology services market growth in Latin America.

The COVID-19 pandemic has impacted every aspect of the diagnostics industry in South and Central America, including histopathology. In the last few months, the number of patient visits to hospitals has reduced significantly, despite the continuation of emergency and OPD services. Due to lockdowns enforced in several countries in South and Central America, the number of elective and cancer surgeries have reduced significantly. Moreover, with the steep increase in the incidence of COVID- 19, pathology laboratories are now prioritizing and focusing on COVID-19 diagnosis. A rapid increase in the number of infected patients in Brazil and Argentina is hampering the growth of the histopathology services market performance in the region.

SOUTH AND CENTRAL AMERICA HISTOPATHOLOGY SERVICES MARKET SEGMENTATION

By Type of Examination

• Surgical Specimen
• Breast Biopsy
• Lung Biopsy
• Renal Biopsy
• Gastrointestinal Biopsy
• Pancreatic Biopsy
• Skin Tissue Biopsy
• Testicular Biopsy
• Others

By End User

• Diagnostic Laboratories & Reference Laboratories
• Research Institutes
• Others

By Country

• Brazil
• Argentina
• Rest of South and Central America

Company Profiles

• TPL Path Labs
• UNILABS
• Targos
• CHARLES RIVER LABORATORIES, INC.

South and Central America Histopathology Services Report Scope